- UniQure N.V. QURE and Apic Bio entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
- Under the agreement, UniQure acquired global rights for developing and commercializing APB-102, adding to its pipeline of gene therapies to treat neurological disorders.
- The FDA cleared the investigational new drug application for APB-102 and has granted Orphan Drug and Fast Track designations.
- UniQure expects to initiate a Phase 1/2 clinical study of APB-102 in the second half of 2023.
- Also See: FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults.
- Under the terms of the agreement, UniQure will make an initial cash payment of $10 million. In addition, UniQure will pay Apic Bio up to $45 million in milestones upon achieving regulatory approvals in the U.S. and Europe, pre-specified annual net sales, and a tiered sales-based royalty.
- Analyst Take: SVB Leerink says APB-102 is a good strategic fit for QURE's pipeline, particularly given their expertise with miRNA gene therapy development through their AMT-130 Huntington's disease program.
- It also writes that APB-102 is complementary to QURE's internal AMT-161 gene therapy program for c9orf72 ALS and that it comes to QURE ready for the clinic to provide near-term catalysts.
- While ALS is largely viewed as a high-risk/reward space for drug development, SVB appreciates that QURE is pursuing genetic-targeted approaches.
- Price Action: QURE shares are up 3.51% at $21.37 on the last check Tuesday.
Loading...
Loading...
QUREuniQure NV
$13.052.03%
Edge Rankings
Momentum
97.87
Growth
-
Quality
-
Value
10.64
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
